Thrivent Financial for Lutherans raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 38.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,720 shares of the specialty pharmaceutical company's stock after purchasing an additional 5,440 shares during

DUBLIN , Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026 The Company will host an investor webcast on Friday, January 9, 2026, at 6:30 a.m. PT / 3:30 p.m.

California Public Employees Retirement System cut its stake in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 15.7% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 228,413 shares of the specialty pharmaceutical company's stock after selling 42,387 shares during the

Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and Apogee Therapeutics (NASDAQ: APGE - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations. Valuation and Earnings This table compares Jazz

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes Eight abstracts, including four late-breaking abstracts, underscore Jazz's continued commitment to the epilepsy community and advancing the comprehensive treatment for rare forms of epilepsy For U.S. media and investors only DUBLIN , Dec. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts, including four that are late-breaking, will be presented on Epidiolex® (cannabidiol) at the American Epilepsy Society (AES) 2025 Annual Meeting, being held December 5-9, 2025, in Atlanta, Georgia.   Notable data include new results from the EpiCom trial, an ongoing Phase 3b/4 study evaluating behavioral and other non-seizure outcomes after initiation of adjunctive Epidiolex treatment in participants with tuberous sclerosis complex (TSC)-associated seizures.

Jazz Pharmaceuticals PLC (JAZZ) shares up 352% since Big Money bought big in 2015.

Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to review data For U.S. media and investors only DUBLIN , Dec. 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced two abstracts featuring key data for Ziihera ® (zanidatamab-hrii) have been accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) from January 8-10, 2026, in San Francisco. The Phase 3 HERIZON-GEA-01 trial results in first-line HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) were accepted as a late-breaking presentation.

Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

JAZZ leverages Epidiolex's rising sales and its broad drug portfolio to strengthen its position in the evolving medical cannabis market.